A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study

Pediatric Blood and Cancer

Volumn 57, Issue 2, 2011, Pages 275-282

  Russell, Heidi V ^a   Groshen, Susan G ^b   Ara, Tasnim ^b   Declerck, Yves A ^b   Hawkins, Randy ^c   Jackson, Hollie A ^b   Daldrup Link, Heike E ^c   Marachelian, Araz ^b   Skerjanec, Andrej ^d   Park, Julie R ^e   Katzenstein, Howard ^f   Matthay, Katherine K ^c   Blaney, Susan M ^a   Villablanca, Judith G ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e SEATTLE CHILDREN S HOSPITAL   (United States)

^f EMORY UNIVERSITY   (United States)

Author keywords

Bisphosphonate; Neuroblastoma; Phase I

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; ZOLEDRONIC ACID;

ADOLESCENT; ADULT; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BONE METASTASIS; BONE TURNOVER; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FATIGUE; FEMALE; FEMUR FRACTURE; FRACTURE; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERMAGNESEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFANT; INFECTION; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; OSTEOCLAST; OSTEOLYSIS; OSTEOSCLEROSIS; PAIN; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECOMMENDED DRUG DOSE; RIB FRACTURE; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INFANT; MALE; MAXIMUM TOLERATED DOSE; NEUROBLASTOMA; SURVIVAL ANALYSIS;

EID: 79958844377     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22821     Document Type: Article

References (44)

1. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study. J Clin Oncol 2009; 27: 1007-1013.
2. Green JR, Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 2002; 25: S3-S9.
3. Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: Analysis of a national medical claims database. Cancer 2008; 113: 1438-1445.
4. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191-1200.
5. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
6. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691.
7. McWilliams NB, Hayes FA, Green AA, et al. Cyclophosphamide/doxorubicin vs. cisplatin/teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: A Pediatric Oncology Group Randomized Phase II study. Med Pediatr Oncol 1995; 24: 176-180.
8. Green AA, Hayes FA, Hustu HO. Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastoma. Cancer 1981; 48: 2310-2317.
9. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-1886.
10. Kerbel RS, Viloria-Petit A, Klement G, Rak J. "Accidental" anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000; 36: 1248-1257.
11. Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003; 98: 1643-1648.
12. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13: 73-80.
13. Peng H, Sohara Y, Moats RA, et al. The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res 2007; 67: 9346-9355.
14. Le TC, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009; 101: 708-720.
15. Rosen LS, Gordon DH, Dugan W, Jr., et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100: 36-43.
16. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
18. Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003; 21: 2486-2491.
19. Skerjanec A, Berenson J, Hsu C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003; 43: 154-162.
20. Hogler W, Yap F, Little D, et al. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 2004; 145: 701-704.
21. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003; 111: 1030-1036.
22. Falk MJ, Heeger S, Lynch KA, et al. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 2003; 111: 573-578.
23. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997; 76: 266-283.
24. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008; 74: 1385-1393.
25. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613-2621.
26. Dodson TB. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67: 44-52.
27. Whyte MP, McAlister WH, Novack DV, et al. Bisphosphonate-induced osteopetrosis: Novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J Bone Miner Res 2008; 23: 1698-1707.
28. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: A case control study. Osteoporos Int 2009; 20: 1353-1362.
29. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008; 22: 346-350.
30. Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002; 20: 850-856.
31. Lipton A, Costa L, Ali S, Demers L. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 2001; 28: 54-59.
32. Atkinson SA. Vitamin D status and bone biomarkers in childhood cancer. Pediatr Blood Cancer 2008; 50: 479-482.
33. Tuchman S, Thayu M, Shults J, et al. Interpretation of biomarkers of bone metabolism in children: Impact of growth velocity and body size in healthy children and chronic disease. J Pediatr 2008; 153: 484-490.
34. Egler RA, Burlingame SM, Nuchtern JG, Russell HV. Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clin Cancer Res 2008; 14: 7028-7034.
35. Lauta VM. A review of the cytokine network in multiple myeloma: Diagnostic, prognostic, and therapeutic implications. Cancer 2003; 97: 2440-2452.
36. Soubrane C, Rixe O, Meric JB, Khayat D, Mouawad R. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: A retrospective study. Melanoma Res 2005; 15: 199-204.
37. George DJ, Halabi S, Shepard TF, et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 9480. Clin Cancer Res 2005; 11: 1815-1820.
38. Ara T, Song L, Shimada H, et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 2009; 69: 329-337.
39. Giannitrapani L, Cervello M, Soresi M, et al. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann NY Acad Sci 2002; 963: 46-52.
40. Kovacs E. Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomed Pharmacother 2001; 55: 391-396.
41. Knupfer H, Preiss R. sIL-6R: More than an agonist? Immunol Cell Biol 2008; 86: 87-91.
42. Dowdall JF, Winter DC, Andrews E, et al. Soluble interleukin 6 receptor (sIL-6R) mediates colonic tumor cell adherence to the vascular endothelium: A mechanism for metastatic initiation? J Surg Res 2002; 107: 1-6.
43. Jablonska E. Release of soluble IL-6 receptor (IL-6sR) in comparison with release of soluble TNF receptors (sTNF-Rs) by PMNs and WBC derived from breast cancer patients. Cancer Lett 1997; 119: 79-85.
44. Saily M, Koistinen P, Savolainen ER. The soluble form of interleukin-6 receptor modulates cell proliferation by acute myeloblastic leukemia blast cells. Ann Hematol 1999; 78: 173-179.